The Week in Review: April 20 – April 27, 2018

Friday, April 27, 2018 News Recap: Warnings: Synthetic cannabinoids and Hepatitis A could be a fatal combination. On April 9, 2018, the Missouri Department of Health and Senior Services (DHSS) issued a news release – “Use of Synthetic Cannabinoids Linked to Severe Bleeding in the US,” informing the public about the national outbreak of bleeding illnesses among those consuming synthetic cannabinoids which appear to have been contaminated with a long-...

The Sum is More Than the Parts: Effects of HIV and Alcoholism or Hepatitis C on the Brain

As the medications for HIV have gotten more effective, people are living longer with HIV. However, as people living with HIV get older, they are more likely to also develop different problems or diseases, two of which include the viral infection Hepatitis C and Alcohol Use Disorder (alcoholism). In terms of medical and psychiatric effects, age-related medical conditions (like diabetes, high blood pressure, Alzheimer’s Disease) can occur earlier in life in

The Week in Review: April 6 – April 13, 2018

Friday, April 13, 2018 News Recap: Canada: Initiative aims to treat Hepatitis C in Alberta patients who also have HIV. A long-term effort to eliminate Hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to...

Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind

Worldwide, 71 million people are infected with hepatitis C virus (HCV), which, without treatment, can lead to liver failure or hepatocellular carcinoma. HCV co-infection increases liver- and AIDS-related morbidity and mortality among HIV-positive people, despite ART. A 12-week course of HCV direct-acting antivirals (DAAs) usually cures HCV – regardless of HIV status. However, patents and high prices have created access barriers for people living with HCV,

DAAs produce cure rates in HCV/HIV co-infection similar to monoinfection

Using direct-acting antiviral therapies demonstrated similarly high rates of sustained virologic response for hepatitis C virus infection in patients with and without HIV infection as compared with rates for HCV mono-infected patients, according to findings published in Hepatology. “Because of low [sustained virologic response] rates associated with interferon-based therapies, the accelerated progression of HCV related liver disease, and barriers to recei

The Week in Review: October 13 – October 20, 2017

Friday, October 20, 2017 News Recap: Disease Management: Women: Hepatitis C in pregnancy: screening, treatment, and management. Hepatitis C (HCV) during pregnancy is associated with serious, adverse outcomes. Infants born to women with HCV are more likely to experience fetal growth restriction and low birth weight. For women, chronic HCV is associated with progressive liver damage and, during pregnancy, can be transmitted from the mother to the fe...

Cannabis May Be Protective Against Steatosis in Persons Coinfected with HIV-HCV

MARSEILLE, FRANCE — Cannabis may be protective against liver disease in subjects infected with both the hepatitis C virus (HCV) and the human immunodeficiency virus (HIV), according to data published online ahead of print in the Journal of Viral Hepatitis. French investigators assessed the relationship between cannabis use and the prevalence of steatosis (fatty liver disease) in a cohort of 838 HIV-HCV co-infected subjects. They reported, “Daily cannab

The Week in Review: October 6 – October 13, 2017

Friday, October 13, 2017 News Recap: Research & Discoveries After an intense hunt, researchers at the Norwegian University of Science and Technology (NTNU) can now describe an important part of the disease's guerrilla tactics: how hepatitis C converts innocent cells into outright virus factories.  How hepatitis C hides in the body. Apparently, liver cancer can be caught at an early stage through a newly developed blood test, improving the odd...

Rapid fibrosis progression in large proportion of HIV-positive gay men after acute HCV

Over a third of HIV-positive gay men develop significant liver fibrosis after an episode of acute hepatitis C virus (HCV) infection, German investigators report in the Journal of Viral Hepatitis. Over three years of follow-up, 39% of individuals developed fibrosis stage F2 or higher. Risk factors included older age, alcoholism and non-response to therapy based on interferon during acute infection. Highly effective HCV therapy using direct-acting antiviral

The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...